Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2026 16:00 ET | Source: Elion Therapeutics

Elion Therapeutics Announces Initiation of Turletricin (EL219) Phase 2 Study in Invasive Mould Infection

Elion Therapeutics initiated a Phase 2 study of turletricin in invasive mould infection ("TREAT-1") and is presenting early clinical data at ESCMID 2026.